Using proteomic profiling to characterize protein signatures of different thymoma subtypes

BMC Cancer

Table 3 Pathway analysis of differentially expressed proteins for each subtype of thymoma

Canonical Pathway^a	-log(P-value) ^b	Ratio^c
Subtype AB
Acute Phase Response Signaling	6.96	0.05
Complement System	3.18	0.08
Apoptosis Signaling	3.07	0.04
Triacylglycerol Degradation	3.05	0.08
Granzyme B Signaling	2.59	0.13
Subtype B2
LXR/RXR Activation	8.06	0.07
FXR/RXR Activation	6.71	0.06
Atherosclerosis Signaling	5.57	0.06
Production of Nitric Oxide and Reactive Oxygen Species in Macrophages	4.31	0.04
IL-12 Signaling and Production in Macrophages	4.10	0.04
Subtype B3
Acute Phase Response Signaling	12.00	0.08
Complement System	7.83	0.17
Coagulation System	4.69	0.11
LXR/RXR Activation	4.68	0.05
FXR/RXR Activation	4.60	0.05

^a Canonical pathway analysis was conducted by the Ingenuity® Pathway Analysis (IPA) program and analyzed based on the Ingenuity® Knowledge Base (Content version: 39480507; Release date: 2017-09-14)
^b Fisher’s exact test was used to determine the enrichment of differentially expressed proteins in a given canonical pathway
^c Ratio represents the number of differentially expressed proteins in the pathway divided by the total number of proteins in the same pathway

ISSN: 1471-2407